Pre-emptive intrathecal administration of an NMDA receptor antagonist (AP-5) prevents hyper-reflexia in a model of persistent visceral pain.
Dorsal horn sensitization following somatic noxious stimuli is partly mediated by the N-methyl-D-aspartate (NMDA) sub-type of glutamate receptor. This phenomenon has been comparatively sparsely investigated in the area of visceral pain. We have therefore investigated the role of spinal NMDA receptors in central sensitization in an animal model of persistent visceral pain. In anaesthetized rats the lumbosacral spinal cord was exposed by laminectomy and the pre-emptive effect of intrathecal AP-5 upon the hyper-reflexia associated with chemical inflammation of the bladder was investigated. The effect of intrathecal AP-5 (an NMDA receptor antagonist) upon the normal cystometrogram (CMG) was also measured. AP-5 (125-1000 micrograms) prevented the hyper-flexia associated with bladder inflammation in a dose-dependant fashion. In general, within the dose range 62.5-1000 micrograms, AP-5 had no significant effect upon the normal micturition reflex. However, at the top of this dose range a minor non-significant depression of this reflex was noted. NMDA receptors do not appear to mediate the micturition reflex at a spinal cord level. However, they are involved in the induction of hyper-reflexia following urinary bladder inflammation, this hyper-reflexia can be prevented by pre-emptive intrathecal administration of AP-5.
Rice
Andrew S C
ASC
Nuffield Department of Anaesthetics and Oxford Regional Pain Relief Unit, OxfordUK Sherrington School of Physiology, UMDS, London SE1 7EH UK.
McMahon
Stephen B
SB
D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D002908:Chronic Disease; D003556:Cystitis / Q000139:chemically induced / Q000503:physiopathology; D004056:Differential Threshold; D004305:Dose-Response Relationship, Drug; D005260:Female; D007278:Injections, Spinal; D010146:Pain; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D012021:Reflex, Abnormal / Q000187:drug effects*; D014554:Urination / Q000187:drug effects; D014781:Viscera
D016194:Receptors, N-Methyl-D-Aspartate; D015763:2-Amino-5-phosphonovalerate